- First international multi-center clinical trial (IMCT) of lemzoparlimab in China   - Second IND approval from China NMPA for lemzoparlimab SHANGHAI and GAITHERSBURG, Md. , Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to

Phase 1 Clinical Study Expected to Start in Q4 2020 PLANEGG/ MUNICH, Germany and SHANGHAI, China , Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S.

SHANGHAI and GAITHERSBURG, Md. , Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in

Ordinary Share Purchase price equivalent to $33.00 per ADS, at a premium to the 30-day volume weighted average price ("VWAP")   Demonstrates leading biotech investors' strong endorsement of I-Mab's R&D innovation and value generation capabilities SHANGHAI and GAITHERSBURG, Md. , Sept.

AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)   I-Mab to receive upfront payment of $180 million   Potential to explore combination therapies with I-Mab's lemzoparlimab and AbbVie's venetoclax

Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global effort against COVID-19 with plonmarlimab (TJM2) study which represents the first double-blind, placebo-controlled study

SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed with plonmarlimab

Conference Call Scheduled for August 31 at 8:00 a.m. ET with Pre-Registration Required SHANGHAI and GAITHERSBURG, Md. , Aug. 6, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of

SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration

SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment of Mr.